How Blood Sugar Monitoring Without Diabetes Is Becoming a Mainstream Health Tool

Continuous glucose monitors are now being worn by people without diabetes for metabolic optimisation. Here is what the data shows and what the science says about whether this makes sense.

Continuous glucose monitors — small sensors worn on the arm that measure blood glucose levels every five minutes without fingerstick — were developed specifically for people with diabetes, whose blood sugar management requires the kind of real-time feedback that CGMs provide. In 2024-2026, they have been adopted in significant numbers by people without diabetes who are using the data for metabolic optimisation, performance monitoring, and dietary self-experimentation.

The specific value proposition for non-diabetic CGM users is that blood glucose variability — the degree to which blood sugar spikes and crashes throughout the day — may be an informative metabolic health marker even within the ranges conventionally considered normal. Research has shown that people without diabetes nonetheless vary considerably in their post-meal glucose excursions, and that higher variability may be associated with worse metabolic outcomes over time even when average glucose is normal.

Companies including Levels, NutriSense, and Supersapiens have built consumer platforms around CGM data interpretation specifically for non-diabetic users. Their value proposition involves helping users understand which foods cause large blood glucose spikes for their individual metabolism, timing meals and exercise to maintain stable glucose levels, and using glucose data as a proxy for metabolic health status.

The honest scientific assessment: for most healthy people without metabolic disease, the CGM data will confirm what evidence-based nutrition already recommends — eating more vegetables and protein, less refined carbohydrate, maintaining consistent meal timing — without providing dramatically personalised insights beyond what general advice covers. The exceptions: people in the prediabetic range who don't know it, people with specific metabolic sensitivities that produce outlier glucose responses, and athletes whose performance is significantly affected by glucose status during training and competition.

For the Kerry 2026 nutrition trends report's characterisation: real-time health monitoring including glucose is 'powering next-gen precision nutrition platforms.' This is accurate as a description of the technology direction. Whether the precision nutrition guidance it enables produces health outcomes meaningfully better than general evidence-based nutrition for most users is a question that requires more and better clinical evidence than currently exists.